BACE: lead target for orchestrated therapy of alzheimer's disease

BACE: lead target for orchestrated therapy of alzheimer's disease

John, Varghese

90,77 €(IVA inc.)

This book covers virtually all aspects of the rapidly developing field of beta secretase (BACE) from the original isolation and cloning of BACE, to the discovery of various classes of BACE inhibitors, and challenges in clinical development. This provides every member of the diverse drug-discovery team with global understanding essential for productive and successful drug discovery, as well as offers researchers and clinicians an overview of the ground-breaking progress that has been made to develop inhibitors of BACE as efficacious treatments for Alzheimer's disease.Varghese John is Director of Drug Discovery at the Buck Institute for Age Research. He is a chemist with 18 years of pharmaceutical industry experience, atElan Pharmaceuticals and Athena Neuroscience, in development of drugs for CNSdiseases with a primary focus on Alzheimers disease (AD). Dr. John has 24 publications and 65 patents to his credit.

  • ISBN: 978-0-470-29342-3
  • Editorial: John Wiley & Sons
  • Encuadernacion: Cartoné
  • Páginas: 266
  • Fecha Publicación: 16/03/2010
  • Nº Volúmenes: 1
  • Idioma: Inglés